Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2021 16:01 ET | Source: OpGen, Inc.

OpGen Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Total combined pro-forma revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.4 million cash as of December 31, 2020 Raised an additional $34.7 million of capital...
March 11, 2021 07:30 ET | Source: OpGen, Inc.

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2020

GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth...
March 08, 2021 07:30 ET | Source: OpGen, Inc.

OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of Bacterial Co-Infections in ICU Patients with COVID-19 Pneumonia

Karolinska Institutet Study highlights Unyvero HPN demonstrating a higher diagnostic yield than bacterial culture, enabling rapid diagnosis of pathogens of concern in these patients High negative...
March 01, 2021 07:30 ET | Source: OpGen, Inc.

OpGen Wins Chinese NMPA Approval for the Curetis Unyvero System

Chinese regulatory authority NMPA completes registration of Unyvero instrument system as IVD for Chinese marketApplication of Unyvero cartridge for pneumonia is under review and pending NMPA...
February 16, 2021 07:30 ET | Source: OpGen, Inc.

OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction of Antibiotic Susceptibility Testing by Next-Generation Sequencing

Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data Publication supports harmonization of the development of good machine...
February 09, 2021 08:30 ET | Source: OpGen, Inc.

OpGen, Inc. Announces $25 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

GAITHERSBURG, Md., Feb. 09, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat...
January 13, 2021 07:30 ET | Source: OpGen, Inc.

OpGen Announces Preliminary Unaudited Revenue for Fiscal 2020 and Provides Business Update

Preliminary total pro-forma combined revenue for 2020 was approximately $5.2 millionMaintained strong balance sheet with $13.3 million cash as of December 31, 2020 and total capital raised in 2020 of...
January 05, 2021 07:30 ET | Source: OpGen, Inc.

OpGen Subsidiary Curetis and Annar Enter into Unyvero Distribution Partnership for Colombia

Exclusive distribution agreement for initial term of three yearsAnnar commits to minimum purchase of 10 Unyvero systems during initial term Annar to seek regulatory clearance for Unyvero products in...
December 17, 2020 08:00 ET | Source: OpGen, Inc.

Results from 1,400 Patient Sample Multicenter Study Published: Unyvero LRT BAL Panel Provides Accurate Detection in Bronchoalveolar Lavage Fluid, Allowing Enhanced Diagnosis of Lower Respiratory Tract Infections

Early diagnosis and proper choice of antimicrobials are crucial for successful management of pneumoniaStudy demonstrates Unyvero LRT BAL provides accurate detection of common agents of bacterial...
December 09, 2020 07:30 ET | Source: OpGen, Inc.

OpGen Announces Planned Leadership Transition at Next Generation Sequencing and Bioinformatics Subsidiary Ares Genetics

Dr. Arne Materna to join Ares Genetics as new Managing Director and CEO to lead Ares into next phase of its growth Dr. Andreas Posch, while stepping down as Managing Director and CEO to pursue new...